USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
IGC Pharma (NYSE:IGC) announced that the USPTO granted U.S. Patent No. 12,465,589 on November 11, 2025 for "Methods and Composition for Treating CNS Disorders."
The patent covers the proprietary formulation used in IGC-AD1, the company's lead candidate now in the Phase 2 CALMA trial for agitation in Alzheimer's disease, and claims effects on amyloid-beta, tau phosphorylation, mitochondrial function, and behavioral symptoms including agitation, memory, cognition, anxiety, and sleep disturbances.
IGC Pharma (NYSE:IGC) ha annunciato che l’USPTO ha concesso l’11 novembre 2025 la patente statunitense n. 12,465,589 per "Metodi e Composizioni per il Trattamento dei Disturbi del SNC".
La patente copre la formulazione proprietaria utilizzata in IGC-AD1, il candidato principale dell’azienda attualmente nello studio di fase 2 CALMA per l’agitazione nella malattia di Alzheimer, e rivendica effetti su amiloide-beta, fosforilazione di tau, funzione mitocondriale e sintomi comportamentali tra cui agitazione, memoria, cognizione, ansia e disturbi del sonno.
IGC Pharma (NYSE:IGC) anunció que la USPTO concedió la patente estadounidense n.º 12,465,589 el 11 de noviembre de 2025 para "Métodos y Composición para Tratar Trastornos del SNC".
La patente cubre la formulación propietaria utilizada en IGC-AD1, el candidato principal de la compañía que ahora se encuentra en el ensayo de fase 2 CALMA para la agitación en la enfermedad de Alzheimer, y reclama efectos sobre amyloid-beta, fosforilación de tau, función mitocondrial y síntomas conductuales incluyendo agitación, memoria, cognición, ansiedad y trastornos del sueño.
IGC Pharma (NYSE:IGC)가 미국 특허청(USPTO)이 2025년 11월 11일에 중추신경계 장애 치료용 방법 및 조성물에 대한 미국 특허 번호 12,465,589를 부여했다고 발표했습니다.
이 특허는 IGC-AD1에 사용된 독점 제형을 다루며, 현재 알츠하이머 병의 진전된 제4상 CALMA 시험에서 제2상 단계인 후보 물질이고, 아밀로이드-베타, 타우 인산화, 미토콘드리아 기능 및 불안, 기억, 인지, 불안, 수면 장애를 포함한 행동 증상에 대한 효과를 주장합니다.
IGC Pharma (NYSE:IGC) a annoncé que l’USPTO a accordé le 11 novembre 2025 le brevet américain n° 12,465,589 pour « Méthodes et composition pour le traitement des troubles du SNC ».
Le brevet couvre la formulation propriétaire utilisée dans IGC-AD1, le candidat phare de la société actuellement dans l’essai de phase 2 CALMA pour l’agitation dans la maladie d’Alzheimer, et revendique des effets sur l’amyloïde-bêta, la phosphorylation de tau, la fonction mitochondriale et des symptômes comportementaux incluant l’agitation, la mémoire, la cognition, l’anxiété et les troubles du sommeil.
IGC Pharma (NYSE:IGC) kündigte an, dass das USPTO am 11. November 2025 das US-Patent Nr. 12,465,589 für 'Methoden und Zusammensetzung zur Behandlung von ZNS-Störungen' erteilt hat.
Das Patent deckt die firmeneigene Formulierung ab, die in IGC-AD1 verwendet wird, dem führenden Kandidaten des Unternehmens, der sich derzeit in der Phase-2 CALMA-Studie zur Agitation bei der Alzheimer-Krankheit befindet, und beansprucht Wirkungen auf Amyloid-beta, Tau-Phosphorylierung, mitochondriale Funktion und Verhaltenssymptome einschließlich Agitation, Gedächtnis, Kognition, Angst und Schlafstörungen.
IGC Pharma (NYSE:IGC) أعلنت أن USPTO منحت البراءة الأمريكية رقم 12,465,589 في 11 نوفمبر 2025 لـ "طرائق ومركب لعلاج اضطرابات الجهاز العصبي المركزي".
وتغطي البراءة الصيغة المملوكة المستخدمة في IGC-AD1، وهو المرشح الرائد للشركة الذي يوجد حاليًا في تجربة CALMA من المرحلة 2 للهيجان/الارتباك في مرض الزهايمر، وتدعي تأثيرات على أميلويد-بيتا، فوسفورة تاو، وظيفة ميتوكوندريّة، وكذلك على الاضطرابات السلوكية بما في ذلك الهيجان، الذاكرة، الإدراك، القلق، واضطرابات النوم.
- USPTO grant of U.S. Patent No. 12,465,589 on November 11, 2025
- Patent covers IGC-AD1 composition targeting amyloid, tau, mitochondrial dysfunction, and symptoms
- IGC-AD1 is an active asset in a Phase 2 CALMA trial for agitation in Alzheimer's disease
- Patent grant does not equal FDA approval or demonstrated clinical efficacy
Insights
USPTO patent for IGC-AD1 strengthens IP around a Phase 2 Alzheimer’s candidate; watch clinical readouts and commercialization steps.
IGC Pharma now holds U.S. Patent No. 12,465,589 granted on
The value of the patent lies in legal exclusivity over the described formulation and methods, which can support development and later commercialization. Key dependencies remain: the ongoing Phase 2 CALMA trial must demonstrate safety and efficacy for the patent to translate into commercial value, and granted claims apply only to the disclosed composition and methods as written. The patent text also limits analysis to the exact claims; broader therapeutic claims are not asserted here.
Near-term items to watch include the Phase 2 CALMA interim and final readouts and any regulatory or partnering announcements; note the patent grant date of
POTOMAC, MARYLAND / ACCESS Newswire / November 13, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office ("USPTO") has granted the company U.S. Patent No. 12,465,589, titled "Methods and Composition for Treating CNS Disorders." The patent covers the propriety formulation used in IGC-AD1, the Company's lead drug candidate currently being evaluated in the Phase 2 CALMA (Clinically Advanced Lead Molecule for Agitation) trial for agitation in Alzheimer's disease.
The patent granted on November 11, 2025, covers a proprietary composition for treating Alzheimer's disease including amyloid plaque, tau tangles as well as symptoms associated with Alzheimer's, such as agitation, memory, cognition, anxiety, and sleep disturbances.
Ram Mukunda, CEO of IGC Pharma, commented, "This patent further strengthens the robustness of our intellectual property portfolio as we move closer to commercialization of IGC-AD1. It reinforces our position in developing differentiated therapies that target both the behavioral and disease-modifying aspects of Alzheimer's disease, with the goal of delivering safer, more effective solutions for patients and caregivers."
This patented composition is designed to reduce amyloid-beta (Aβ) expression and aggregation, enhance mitochondrial function, decrease phosphorylation of GSK3β, and lower tau phosphorylation, thereby addressing both behavioral symptoms and core disease mechanisms of Alzheimer's. Importantly, the combination seeks to achieve these effects without serious side effects, a critical advancement in the development of safer, more effective therapies for neurodegenerative diseases.
The company's research focus continues to target the mechanisms that underlie Alzheimer's progression, including Aβ aggregation, tau pathology, mitochondrial dysfunction, and neuroinflammation-pathways long associated with cognitive decline and behavioral symptoms.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Rosalyn Christian/John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What does USPTO U.S. Patent No. 12,465,589 granted on November 11, 2025 cover for IGC (NYSE:IGC)?
How does the November 11, 2025 patent affect IGC-AD1's commercialization prospects for IGC (NYSE:IGC)?
What stage is IGC-AD1 in and what trial is ongoing as of November 13, 2025 for IGC (NYSE:IGC)?
Does the patent announcement for IGC (NYSE:IGC) include Phase 2 CALMA clinical results?
Which Alzheimer's disease mechanisms does the IGC (NYSE:IGC) patent claim to address?
